Biocon Limited (BOM:532523)
India · Delayed Price · Currency is INR | Market Cap | 470.39B |
| Revenue (ttm) | 157.71B |
| Net Income (ttm) | 3.85B |
| Shares Out | n/a |
| EPS (ttm) | 3.21 |
| PE Ratio | 122.18 |
| Forward PE | 55.94 |
| Dividend | 0.50 (0.14%) |
| Ex-Dividend Date | Jul 4, 2025 |
| Volume | 48,009 |
| Average Volume | 103,719 |
| Open | 347.95 |
| Previous Close | 348.70 |
| Day's Range | 347.95 - 356.35 |
| 52-Week Range | 290.80 - 405.90 |
| Beta | n/a |
| RSI | 48.25 |
| Earnings Date | Nov 11, 2025 |
About Biocon
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, a... [Read more]
Financial Performance
In 2024, Biocon's revenue was 152.62 billion, an increase of 3.43% compared to the previous year's 147.56 billion. Earnings were 10.13 billion, a decrease of -0.90%.
Financial StatementsNews
Biocon subsidiary, in partnership with Carnegie Pharmaceuticals, gets USFDA tentative nod for Rifaximin Tablets 550 mg
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Ltd, has received tentative approval from the U.S. Food and Drug...
Equillium (EQ) Ends Collaboration with Biocon on Itolizumab
Equillium (EQ) Ends Collaboration with Biocon on Itolizumab
Biocon Biologics secures U.S. launch for Bosaya and Aukelso following settlement with Amgen
Biocon Biologics Ltd. (BBL), a global leader in biosimilars and a subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), has announced a key settlement and license agreement with Amgen Inc., paving the...
Not a med emergency: Generic pharma cos spared from harm
Trump's new 100% pharma levy primarily targets branded and patented medicines, potentially impacting Sun Pharma and Biocon's US sales. While most Indian generic firms anticipate business as usual, som...
Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street
Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump's announcement of 100% tariffs on imported branded medicines to the US. Companies like Sun Pharma, Biocon, and Zyd...
Biocon shares fall over 3% after Trump’s pharma tariff announcement
Shares of Biocon Ltd slipped 3.44% to ₹343.70 on Friday, September 26, reacting to U.S. President Donald Trump’s announcement of a 100% tariff on branded and patented pharmaceutical imports starting O...
How To Fix Bengaluru's Civic Problem? Kiran Mazumdar Shaw Speaks To NDTV
Bengaluru's crumbling civic infrastructure may finally receive a coordinated action plan, with Biocon founder Kiran Mazumdar Shaw urging both officials and citizens to share responsibility in cleaning...
Top stocks to watch today, September 19: Adani Group, NTPC, JSW Energy, Vedanta, Biocon, Waaree Energies and more
Indian equity markets are set for an active session on Friday, September 19, with several companies making headlines due to regulatory updates, acquisitions, partnerships, and project wins. Here are t...
Biocon Biologics’ Yesafili gains public funding in Ontario for Retinal Disease Treatment
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., has achieved a key milestone in Canada with its biosimilar aflibercept, Yesafili®, now publicly funded on the Ontario Drug Benefit (ODB) Formu...
Biocon shares rise nearly 2% after US FDA approves denosumab biosimilars Bosaya™ and Aukelso™
Shares of Biocon Ltd. gained almost 2% on Thursday, trading at ₹360.85, after its subsidiary Biocon Biologics Ltd. (BBL) announced a major regulatory milestone in the U.S. market. The U.S. Food and Dr...
Top stocks to watch today, September 18: TVS Motor, Biocon, Aurobindo Pharma, Bandhan Bank, Federal Bank and more
Indian stock markets are set for another action-packed session on Thursday, September 18, with several corporate developments expected to keep select stocks in focus. Here are the top companies likely...
Biocon Biologic secures U.S. FDA approval for Bosaya and Aukelso, Denosumab Biosimilars
Biocon Biologics Ltd. (BBL), a global leader in biosimilars and a subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), has achieved a significant milestone in the U.S. market. The U.S. Food and Drug ...
"Emergency Measures Needed": India Inc Flags Bengaluru Civic Issues
Kiran Mazumdar-Shaw, executive chairperson of Biocon and a key voice of India Inc., has called for "emergency measures" to address civic issues in Bengaluru after the CEO of a trucking company announc...
Profit margins, US medicine supplies may get hit: Biocon
Biocon anticipates potential challenges from proposed US tariffs on pharmaceutical imports, which could squeeze profit margins and affect the affordability of generic medicines. With the US being its ...
Biocon Q1 net profit falls 95% to Rs 31 crore
Biocon's consolidated net profit plummeted by 95% to Rs 31 crore in the June quarter, with total revenue declining to Rs 4,022 crore. Despite this, operating revenue increased by 15% YoY, driven by Bi...
Biocon Biologics launches Nepexto, a biosimilar to Enbrel, in Australia
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced the launch of Nepexto®, its biosimilar to the reference product Enbrel® (Etanercept), ...
Top stocks in focus on July 16: Biocon, Dixon Technologies, IndiGo, ICICI Lombard, HDFC Life and more
Indian stock markets are expected to witness stock-specific action on Wednesday, July 16, as a series of corporate developments, quarterly earnings, and regulatory updates come into play. Stocks to Wa...
Biocon to announce Q1 FY26 results on August 7
Biocon Limited has informed stock exchanges that its Board of Directors will meet on Thursday, August 7, 2025, to approve and take on record the unaudited standalone and consolidated financial results...
It’s wrong to blame Covid jabs for cardiac arrests: Biocon chief Kiran Mazumdar-Shaw
Bengaluru: Days after chief minister Siddaramaiah blamed Covid-19 vaccines for the alarming rise in cardiac arrest cases among youngsters in the recen.
'Caution Not Anti-Science': Siddaramaiah On Covid Vaccine-Sudden Death Claim
Karnataka Chief Minister Siddaramaiah has responded to Biocon Ltd Executive Chairperson Kiran Mazumdar-Shaw's suggestion that he acknowledge the science behind vaccine development, rather than engage ...
Biocon Chief Counters Siddaramaiah's Covid Vaccine-Heart Attack Link Claim
Biocon chief Kiran Mazumdar-Shaw has pushed back against Karnataka Chief Minister Siddaramaiah's recent claim that COVID-19 vaccines may be linked to a surge in sudden cardiac deaths in Hassan distric...
Biocon Biologics gets marketing authorisation from EC for Denosumab Biosimilars Vevzuo and Evfraxy
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a leading global biosimilars company, has received marketing authorisation from the European Commission (EC) for its biosimilars Vevzuo® and ...
India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents on...
Biocon subsidiary gets Health Canada nod for YESAFILI
Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., has received a Notice of Compliance from Health Canada for YESAFILI™ (aflibercept), marking a significant milestone in the company’s global bi...
Biocon shares in focus as company reportedly plans to launch QIP to raise up to Rs 4,500 crore
Biocon Ltd is reportedly preparing to launch a Qualified Institutional Placement (QIP) to raise as much as ₹4,500 crore, possibly as early as this week, according to a Moneycontrol report. As per the ...